Minocycline is an off-the shelf anti-inflammatory and anti-apoptotic drug that is neuroprotective in animal models of stroke, trauma, and neurodegenerative disorders, and also prolongs survival and reduces motor neuron loss in transgenic mouse models of ALS. Phase II trials suggested that minocycline could be taken safely by patients with ALS. On the basis of these positive results plans were made for many trials of minocycline in neurodegenerative conditions.
Dr Paul H Gordon (Columbia University, New York, USA) and colleagues in the United States Western ALS Study Group did a randomised phase III trial to test the efficacy of minocycline as a treatment for ALS in 412 patients. Compared with patients who took placebo, minocycline-treated patients deteriorated at a 25% faster rate according to the ALS functional rating scale (ALSFRS-R), and showed non-significant tendencies towards faster decline of forced vital capacity (FVC) and muscle strength.
In light of these findings, the authors suggest that trials of minocycline in other neurological diseases should be reassessed, as minocycline might be detrimental in patients with neurological diseases other than ALS. They conclude: “Our results are contrary to many published reports from laboratories, and thus have implications for trials of minocycline in patients with other neurological conditions, for the preclinical evaluation of potential neuroprotective therapies, and for the design of future clinical trials in ALS”.
In an accompanying comment Dr Michael Swash highlights the need for early diagnosis in ALS: “Clinicians and patients alike would prefer ALS therapy to be tested as early as possible, but there are unresolved difficulties with accurate early diagnosis, particularly the absence of a specific diagnostic test. Might some of the compounds that have failed in clinical trials show benefit if tested at disease onset in human beings?” He concludes that the time has come for new approaches to trial design: “The aim must be to design informative, short, inexpensive, and sensitive phase I/II studies before large phase III studies are attempted”.
Tony Kirby | alfa
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences